Overall, these demonstrate that treatment with NDV-ICOSL with CTLA-4 blockade is associated with expansion and activation of CD8+ lymphocytes in the treated tumours, spleen and distant tumours, suggesting that this population of cells may be responsible for the observed increase in therapeutic efficacy. The gene discussed is CD8A; the disease is neoplasm.